Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma

Summary

Study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma. Due to changes in the RCC treatment landscape, info gained is no longer clinically relevant to patients. Data collected is deemed sufficient to meet objective.

Timeline

Start

2012-04-19

Primary completion

2016-11-18

Completion

2016-11-18

Outcome

Outcome not reported

Stopped: “As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that information gained so far by CATChEz study is sufficient.”

Drugs

Indications